Navigation Links
IDRI Announces Appointment of H. Stewart Parker as Chief Executive Officer
Date:2/15/2011

SEATTLE, Feb. 15, 2011 /PRNewswire-USNewswire/ -- The Infectious Disease Research Institute (IDRI) announces today the appointment of H. Stewart Parker as its new Chief Executive Officer and new member of the IDRI board of directors.  Parker is a widely recognized figure in the biotechnology industry, having served as President and CEO of Targeted Genetics Corp. and, formerly, Vice President, Corporate Development at Immunex Corp.

"I look forward to working with Stewart, who represents a balance of entrepreneurial spirit and operational expertise," said Steve Reed, IDRI's Founder and Head of Research and Development.

"I couldn't be more thrilled to join IDRI.  The organization possesses a number of technologies that may have an enormous impact on the health of the world," indicated Parker.  "To support their innovation, IDRI possesses developmental capabilities that are rare in non-profits ― yet urgently needed if global health funding is going to result in products that make a difference."  

Currently a Commercialization Consultant with the Washington Biotechnology & Biomedical Association (WBBA), Parker sits on a number of boards including OncoGenex and C3 Jian Inc. Parker was a long-term board member of Biotechnology Industry Organization (BIO).  She earned an MBA from the University of Washington Foster School of Business.  

"The board conducted an exhaustive international search as we sought the best candidate to lead IDRI," says Franklyn Prendergast, M.D., Ph.D. "Stewart's strength and status as a highly respected CEO made her a unique fit with IDRI's team, as well as with our core values and mission."

The appointment follows the announcement of several new grants that ensures IDRI's continuing success in the area of vaccine development, drug discovery, and diagnostics.

About IDRI – Translating science into global health solutions

IDRI is a Seattle-based not-for-profit organization committed to applying innovative science to the research and development of products to prevent, detect, and treat infectious diseases of poverty. By integrating capabilities — including early stage drug discovery, preclinical testing, manufacturing, and clinical trials — IDRI strives to create an efficient pathway bringing scientific innovation from the laboratory to the people who need it most.

For more information, go to www.idri.org.


'/>"/>
SOURCE Infectious Disease Research Institute (IDRI)
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Lab-on-a-Chip - ICAP Ocean Tomo Announces Auction of Patents for Advanced Techniques in Bio-Organic Analysis and Synthesis
2. Core Informatics Announces Second Office Location in Cambridge Massachusetts
3. RadQual, LLC Announces a New Industry Leading Dose Calibrator Reference Standard
4. Genesis Biopharma Announces Management and Board Changes
5. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011
6. Orexigen® Therapeutics Announces Corporate Realignment
7. Talecris Biotherapeutics Announces Teleconference and Webcast Information for Special Meeting of Shareholders
8. Emergency Nurses Association Announces Corporate Sponsors for Leadership Conference
9. Stem Cell Assurance Announces Engagement of Marcum LLP as its Independent Auditors
10. Pancreatic Cancer Action Network Announces New Initiative to Double the Survival Rate for Pancreatic Cancer Patients by 2020
11. Thermal Gradient Announces Breakthrough in Fast PCR Device Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... Nov. 30, 2016  The Allen Institute for ... the first publicly available collection of gene edited, ... target key cellular structures with unprecedented clarity. Distributed ... powerful tools are a crucial first step toward ... understand what makes human cells healthy and what ...
(Date:11/30/2016)... , Nov. 30, 2016  Tempus, a ... cancer care, and Penn,s Abramson Cancer Center have ... a positive response to immunotherapy treatment based on ... As part of a research collaboration, Tempus ... and melanoma cancer patient data to Penn. Utilizing ...
(Date:11/30/2016)... , 30. November 2016   Merck ... heute die Unterzeichnung einer Reihe von Vereinbarungen ... wird Evotec AG Screeningleistungen für Mercks Palette ... Der Zugriff auf diese Bibliotheken in Kombination ... einen schnelleren Weg zur Ermittlung und Erforschung ...
(Date:11/30/2016)... --  Merck , a leading science and technology company, ... of agreements with Evotec AG, whereby Evotec AG will ... such as CRISPR and shRNA libraries. Combining access to ... pathway to explore and identify new drug targets. ... targets, a process that can be time- and labor-intensive," ...
Breaking Biology Technology:
(Date:11/22/2016)... MINNETONKA, Minn. , Nov. 22, 2016   ... that supports the entire spectrum of clinical research, is ... by Medical LiveWire Healthcare and Life Sciences Awards ... This award caps off an unprecedented year of recognition ... clinical trials for over 15 years. iMedNet ...
(Date:11/16/2016)... , Nov. 16, 2016 Sensory Inc ... and security for consumer electronics, and VeriTran ... and retail industry, today announced a global partnership ... way to authenticate users of mobile banking and ... TrulySecure™ software which requires no specialized biometric ...
(Date:6/27/2016)... 27, 2016 Research and Markets has announced ... report to their offering. ... to grow at a CAGR of 12.28% during the ... on an in-depth market analysis with inputs from industry experts. The ... coming years. The report also includes a discussion of the key ...
Breaking Biology News(10 mins):